The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Abstract
Background Low-molecular-weight heparins such as enoxaparin are preferred for prevention of venous thromboembolism after major joint replacement. Apixaban, an orally active factor Xa inhibitor, might be as effective, have lower bleeding risk, and be easier to use than is enoxaparin. We assessed efficacy and safety of these drugs after elective total knee replacement.Methods In ADVANCE-2, a multicentre, randomised, double-blind phase 3 study, patients undergoing elective unilateral or bilateral total knee replacement were randomly allocated through an interactive central telephone system to receive oral apixaban 2.5 mg twice daily (n=1528) or subcutaneous enoxaparin 40 mg once daily (1529). The randomisation schedule was generated by the Bristol-Myers Squibb randomisation centre and stratified by study site and by unilateral or bilateral surgery with a block size of four. Investigators, patients, statisticians, adjudicators, and steering committee were masked to allocation. Apixaban was started 12-24 h after wound closure and enoxaparin 12 h before surgery; both drugs were continued for 10-14 days, when bilateral ascending venography was scheduled. Primary outcome was the composite of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment. The statistical plan required non-inferiority of apixaban before testing for superiority; analysis was by intention to treat for non-inferiority testing. The study is registered at ClinicalTrials.gov, number NCT00452530.Findings 1973 of 3057 patients allocated to treatment (1528 apixaban, 1529 enoxaparin) were eligible for primary efficacy analysis. The primary outcome was reported in 147 (15%) of 976 apixaban patients and 243 (24%) of 997 enoxaparin patients (relative risk 0.62 [95% CI 0.51-0.74]; p<0.0001; absolute risk reduction 9.3% [5.8-12.7]). Major or clinically relevant non-major bleeding occurred in 53 (4%) of 1501 patients receiving apixaban and 72 (5%) of 1508 treated with enoxaparin (p=0.09).Interpretation Apixaban 2.5 mg twice daily, starting on the morning after total knee replacement, offers a convenient and more effective orally administered alternative to 40 mg per day enoxaparin, without increased bleeding.Funding Bristol-Myers Squibb; Pfizer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [320]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citationEriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Kakkar, A. K., Brenner, B., Dahl, O. E., Eriksson, B. I., Mouret, P., Muntz, J., Soglian, A. G., Pap, Á. F., Misselwitz, F., & Haas, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60880-6 · Cited by 1,070
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
Self-citation
Cited by
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,005
Metadata
- Authors
- Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P.
- Affiliations
- University of Copenhagen (DK)
- University of Oklahoma Health Sciences Center (US)
- South Australia Pathology (AU)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Lassen, Michael Rud
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 375
- Issue
- 9717
- Pages
- 807-815
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2114189419
- Cited by
- 777
- References
- 23
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 26 · 2023: 13 · 2022: 24 · 2021: 34 · 2020: 32 · 2019: 37 · 2018: 34 · 2017: 39 · 2016: 52 · 2015: 53 · 2014: 66 · 2013: 111 · 2012: 107
- FWCI
- 92.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Surgery › Total Knee Arthroplasty Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total knee arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, low molecular weight heparin, non-inferiority, bleeding risk, postoperative thromboprophylaxis, oral anticoagulants
- MeSH terms
- Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Fibrinolytic Agents, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Enoxaparin, Arthroplasty, Replacement, Knee, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. https://app.cochat.ai/papers/10.1016/s0140-6736(09)62125-5
- The paper
- Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P. (2010). Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. The Lancet. https://doi.org/10.1016/s0140-6736(09)62125-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.